Rimegepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist and is currently under development by Biohaven Pharmaceuticals for the acute and preventive treatment of migraine. Among patients with acute migraine, significant clinical efficacy has been reported with a rimegepant single dose. The completed pivotal phase II and III trials showed a beneficial action of rimegepant in terms of pain freedom, pain relief, release of migraine symptoms and lifestyle recovery. Moreover, adverse events were mild or moderate and did not cause trial discontinuation. Several clinical trials are currently ongoing to evaluate long-term safety and efficacy profiles in patients with migraine and refractory trigeminal neuralgia. Drug–drug interactions potentially affecting rimegepant pharmacokinetics should be assessed in future clinical trials.

Rimegepant. calcitonin gene-related peptide (CGRP) receptor antagonist, treatment of migraine / Lionetto, L.; Capi, M.; Curto, M.; Cipolla, F.; Guglielmetti, M.; Martelletti, P.. - In: DRUGS OF THE FUTURE. - ISSN 0377-8282. - 44:8(2019), pp. 635-642. [10.1358/dof.2019.44.8.3024184]

Rimegepant. calcitonin gene-related peptide (CGRP) receptor antagonist, treatment of migraine

Capi, M.;Curto, M.;Cipolla, F.;Martelletti, P.
2019

Abstract

Rimegepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist and is currently under development by Biohaven Pharmaceuticals for the acute and preventive treatment of migraine. Among patients with acute migraine, significant clinical efficacy has been reported with a rimegepant single dose. The completed pivotal phase II and III trials showed a beneficial action of rimegepant in terms of pain freedom, pain relief, release of migraine symptoms and lifestyle recovery. Moreover, adverse events were mild or moderate and did not cause trial discontinuation. Several clinical trials are currently ongoing to evaluate long-term safety and efficacy profiles in patients with migraine and refractory trigeminal neuralgia. Drug–drug interactions potentially affecting rimegepant pharmacokinetics should be assessed in future clinical trials.
2019
Rimegepant; BHV-3000; BMS-927711; migraine; CGRP; CGRP receptor antagonist; gepants
01 Pubblicazione su rivista::01a Articolo in rivista
Rimegepant. calcitonin gene-related peptide (CGRP) receptor antagonist, treatment of migraine / Lionetto, L.; Capi, M.; Curto, M.; Cipolla, F.; Guglielmetti, M.; Martelletti, P.. - In: DRUGS OF THE FUTURE. - ISSN 0377-8282. - 44:8(2019), pp. 635-642. [10.1358/dof.2019.44.8.3024184]
File allegati a questo prodotto
File Dimensione Formato  
Lionetto_Rimegepant_2019.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 233.51 kB
Formato Adobe PDF
233.51 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1310879
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 6
social impact